FinancialContent

LivaNova PLC - Ordinary Shares (NQ:LIVN)

76.43 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about LivaNova PLC - Ordinary Shares

< Previous 1 2 3 4 5 6 7 Next >
News headline image
LivaNova to Announce Third-Quarter 2026 Results
From LivaNova PLC
Via Business Wire
News headline image
LivaNova Director Sells 1,650 Shares for $131,500 ↗
The insider sold 1,650 shares but still retains nearly 8,000 shares. 
Via The Motley Fool
Topics Regulatory Compliance
LivaNova PLC (NASDAQ:LIVN) Combines Strong Growth With a Timely Technical Setup ↗
Via Chartmill
LivaNova (NASDAQ:LIVN) Combines Growth and Reasonable Valuation ↗
Via Chartmill
News headline image
LivaNova to Present at Morgan Stanley and Baird Healthcare Conferences in September
From LivaNova PLC
Via Business Wire
LivaNova (NASDAQ:LIVN) Combines Strong Growth With a Promising Technical Breakout Setup ↗
Via Chartmill
LivaNova (NASDAQ:LIVN) Beats Q2 Earnings Estimates and Raises Full-Year Guidance ↗
Via Chartmill
LivaNova (NASDAQ:LIVN): A Strong Growth Stock with a Constructive Technical Setup ↗
Via Chartmill
LivaNova (NASDAQ:LIVN) Fits the Affordable Growth Profile with Strong Earnings and Relative Value ↗
Via Chartmill
LivaNova Plc (NASDAQ:LIVN) combines fundamental strength and technical timing for a potential breakout. ↗
Via Chartmill
News headline image
LivaNova (LIVN) Q2 2026 Earnings Call Transcript ↗
Record quarterly revenue driven by Essenz upgrades and oxygenator market share gains. 
Via The Motley Fool
Topics Earnings World Trade
News headline image
LivaNova Q2 Earnings Call Highlights ↗
LivaNova (NASDAQ:LIVN) reported record quarterly revenue and adjusted earnings per share for the second quarter of 2026, citing double-digit reported growth across its Cardiopulmonary and Epilepsy... 
Via MarketBeat
Topics Earnings World Trade
News headline image
LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
From LivaNova PLC
Via Business Wire
News headline image
LivaNova to Announce Second-Quarter 2026 Results
From LivaNova PLC
Via Business Wire
LivaNova PLC (NASDAQ:LIVN) Beats Q1 Estimates, Lifts Full-Year Guidance ↗
Via Chartmill
LivaNova (NASDAQ:LIVN) Beats Q4 Estimates, Provides Steady 2026 Outlook ↗
Via Chartmill
News headline image
LivaNova Demonstrates 84.5% Cumulative Response Rate with PolySync Programming in OSPREY Study for Obstructive Sleep Apnea
From LivaNova PLC
Via Business Wire
News headline image
Jette Nygaard-Andersen Joins LivaNova Board as a New Director
From LivaNova PLC
Via Business Wire
News headline image
LivaNova Appoints Anne Liddy as Chief Legal Officer
From LivaNova PLC
Via Business Wire
News headline image
LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit
From LivaNova PLC
Via Business Wire
News headline image
LivaNova to Present at Goldman Sachs Global Healthcare Conference in June
From LivaNova PLC
Via Business Wire
News headline image
LivaNova (LIVN) Q1 2025 Earnings Transcript ↗
LivaNova (LIVN) Q1 2025 Earnings Transcript 
Via The Motley Fool
News headline image
LivaNova (LIVN) Q2 2025 Earnings Transcript ↗
LivaNova (LIVN) Q2 2025 Earnings Transcript 
Via The Motley Fool
Topics Supply Chain
News headline image
LivaNova (LIVN) Q3 2025 Earnings Transcript ↗
LivaNova (LIVN) Q3 2025 Earnings Transcript 
Via The Motley Fool
Topics World Trade
News headline image
LivaNova (LIVN) Q1 2026 Earnings Transcript ↗
LivaNova (LIVN) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
From LivaNova PLC
Via Business Wire
News headline image
Annals of Internal Medicine Publishes 12-Month Results from LivaNova’s OSPREY Clinical Study for Obstructive Sleep Apnea
From LivaNova PLC
Via Business Wire
News headline image
LivaNova to Announce First-Quarter 2026 Results
From LivaNova PLC
Via Business Wire
News headline image
LivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep Apnea
From LivaNova PLC
Via Business Wire
News headline image
LivaNova (LIVN) Q4 2025 Earnings Call Transcript ↗
LivaNova (LIVN) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings World Trade
< Previous 1 2 3 4 5 6 7 Next >